PYXS ▲ +7.0% - Pyxis Oncology, Inc. $PYXS - Pyxis Oncology Announces Positive Updated Data from Phase 1 Monotherapy Study of Micvotabart Pelidotin (MICVO) in Second-Line and Beyond Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (2L+ R/M HNSCC) Pyxis Oncology announced positive updated data from a Phase 1 monotherapy study of its lead candidate micvotabart pelidotin in second-line and beyond recurrent or metastatic head and neck squamous cell carcinoma, driving investor optimism. The encouraging clinical results supported the 7.0% gain in the company's stock price today. 09-SEP-2026 07:00 AM ET